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Abstract
Background: Currently known susceptibility genes such as BRCA1 and BRCA2 explain less than 25% of familial
aggregation of breast cancer, which suggests the involvement of additional susceptibility genes. RNF8, UBC13 and
MMS2 are involved in the DNA damage response pathway and play important roles in BRCA1-mediated DNA
damage recognition. Based on the evidence that several players in the ubiquitin-mediated BRCA1-dependent DDR
seem to contribute to breast cancer predisposition, RNF8, UBC13 and MMS2 were considered plausible candidate
genes for susceptibility to breast cancer.
Methods: The entire coding region and splice junctions of RNF8, UBC13 and MMS2 genes were screened for
mutations in affected index cases from 123 Northern Finnish breast cancer families by using conformation sensitive
gel electrophoresis, high resolution melting (HRM) analysis and direct sequencing.
Results: Mutation analysis revealed several changes in RNF8 and UBC13, whereas no aberrations were observed in
MMS2. None of the found sequence changes appeared to associate with breast cancer susceptibility.
Conclusions: The present data suggest that mutations in RNF8, UBC13 and MMS2 genes unlikely make any sizeable
contribution to breast cancer predisposition in Northern Finland.
Background
Breast cancer is the most frequent malignancy among
women [1], and the presence of a family history is one
of the most fundamental risk factors for the disease [2].
Currently known susceptibility genes including BRCA1,
BRCA2, ATM, CHEK2, PALB2, RAD51C and BRIP1
explain less than 25% of familial breast cancer. The rest
of the cases could be explained by mutations in mainly
moderate and low penetrance cancer susceptibility genes
together with environmental factors. Many of the genes
already associated with breast cancer susceptibility
encode proteins that operate together with BRCA1 and
BRCA2 in the DNA damage response pathway (DDR)
[3-7]. Other genes with similar functions thus represent
good candidates for being new susceptibility genes.
Recent evidence indicates ubiquitin chain formation,
recognitionand breakdown at the site of DNA double-
strand breaks (DSB) as an essential component of the
DDR [8]. RNF8 is a RING-finger ubiquitin ligase (E3),
which is recruited to the sites of DNA damage after
ATM/ATR-dependent phoshorylation of the H2AX his-
tone variant [9-11]. Together with its ubiquitin-conju-
gating enzyme (E2) partner UBC13 it mediates K63-
linked polyubiquitin conjugation to histones H2A and
H2AX. The RNF8/UBC13-dependent histone ubiquityla-
tion is then amplified by the RNF168 E3-ligase acting in
concert with UBC13 [12]. Ubiquitynated histones are
recognized by RAP80 through its ubiquitin interaction
motifs (UIMs), which provide an ubiquitin recognition
element to target the BRCA1 E3 ligase, Abraxas,
MERIT40, BRCC45 and a K63-ubiquitin specific deubi-
quitinating enzyme BRCC36 to DSBs. Each of these
activities is required for appropriate checkpoint and
repair responses to ionizing radiation [13-15]. Depletion
of RNF8 or UBC13 in vitro leads to inhibition of the
recruitment of 53BP1, BRCA1, RAP80 and Abraxas to
DSB sites [9-11,16]. It has also been demonstrated that
the depletion of RNF8 leads to increased ionizing radia-
tion sensitivity and defective G2/M checkpoint [9-11].
In addition, Rnf8
-/- mice display increased genomic
instability and higher risk for tumorigenesis, proposing
that RNF8 is a novel tumor suppressor [17].
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seems to be essential for certain functions of UBC13.
MMS2 forms a complex with UBC13 [18], and this het-
erodimer formation has been demonstrated to be essen-
tial for the DNA damage repair function of UBC13 [19].
Suppression of UBC13 or MMS2 has been shown to
increase the sensitivity to DNA damaging agents [19],
although the exact role of MMS2 in DDR is still unclear
[20].
We have previously reported a potentially deleterious
germline variant of RAP80 (del81E) that abrogated ubi-
quitin binding and DNA damage response in breast can-
cer cases [21]. Additionally, recent findings of an
extensive genome-wide linkage consortium study sug-
gested an association between the rare allele of single
nucleotide polymorphism (SNP) rs8170 in MERIT40
and an increased propensity for hormone receptor-nega-
tive breast cancer, both in the general population and in
BRCA1 mutation carriers [22]. Based on the evidence
that several players in the ubiquitin-mediated BRCA1-
dependent DDR seem to contribute to breast cancer
predisposition (summarized in Table 1), we decided to
examine the role of RNF8, UBC13 and MMS2 in familial
breast cancer by performing a comprehensive mutation
screening of these genes in 123 Northern Finnish breast
cancer families.
Methods
Study population
Affected index cases of 123 breast cancer families from
Northern Finland were screened for germline mutations
in the RNF8, UBC13 and MMS2 genes. From the stu-
died families, 77 were classified as high-risk ones,
defined as follows: 1) three or more cases of breast and/
or ovarian cancer in first or second-degree relatives
(median age 49 years, variation 37-80 years), or 2) two
cases of breast cancer in first- or second-degree rela-
tives, of which at least one with early disease onset (age
≤ 35 years), bilateral disease or multiple primary tumors.
Most of the high-risk families presented three or more
cancer cases. The remaining 46 families with moderate
disease susceptibility indicated two cases of breast can-
cer in first- or second-degree relatives. Fourteen of the
studied index cases had previously been tested positive
for known breast cancer-associated germline mutations
in BRCA1 or BRCA2 (eleven) and PALB2 (three). DNA
samples from anonymous cancer-free female individuals
obtained from Finnish Red-Cross blood donors (N =
104-299, depending on the tested mutation), originating
from the same geographical region as the studied cancer
cases, were used as controls. All patients had given their
informed consent for acquisition of pedigree data and
blood specimens for the study of cancer susceptibility
gene mutations. Approval to perform the study was
obtained from the Ethical Board of the Northern Ostro-
bothnia Health Care District and the Finnish Ministry of
Social Affairs and Health.
DNA extraction and mutation analysis
Genomic DNA was extracted from blood lymphocytes
using either the standard phenol-chloroform method or
the Puregene D-50K purification kit (Gentra, Minneapo-
lis, MN, USA). Mutation screening of the coding regions
and exon-intron boundaries of the RNF8, UBC13 and
MMS2 genes was carried out by conformation sensitive
gel electrophoresis (CSGE) [23], high resolution melting
(HRM) analysis [24], or by direct sequencing. Samples
with band shifts in CSGE or deviant melt curves in
HRM were reamplified and sequenced with Li-Cor IR2
4200-S DNA Analysis system (Li-Cor, Inc., Lincoln, NE,
USA) or with capillary sequencing using ABI3130xl
Genetic Analyzer (Applied Biosystems, Foster City, CA,
USA). For Li-Cor the Sequi Therm EXEL II DNA
Sequencing Kit-LC (Epicentre Technologies, Madison,
WI, USA) and for ABI the Big dye terminator kit v1.1
(Applied Biosystems, Foster City, CA, USA) were used.
Chromatograms were interpreted using CodonCode
Aligner v. 3.5.4 (Codon Code Corporation, Dedham,
MA, USA) and with MEGA4 [25]. Oligonucleotides for
CSGE, HRM and sequencing (Table 2) were designed
using Primer3 software [26], based on sequence infor-
mation obtained from public databases (NC_000006.11,
NC_000012.11 and NC_000008.10).
Statistical and bioinformatical analysis
Carrier frequencies between patients and healthy con-
t r o l sw e r ec o m p a r e db yu s i n gP e a r s o nC h i - S q u a r eo r
Fisher’s exact test in PASW Statistics (version 18 for
Windows, SPSS Inc., Chicago, IL, USA), which was also
used for the generation of odds ratios and confidence
Table 1 Key operators in the BRCA1-dependent ubiquitin
-mediated DNA damage recognition pathway and their
currently known role in breast cancer predisposition
Gene Previous studies on the role
in breast cancer predisposition
Disease related
alterations
RNF8 Not done -
RNF168 Not done
a -
UBC13 Not done
RAP80 Mutation screening [21,27-29] del81E [21]
Abraxas Mutation screening [27,29] N. I.
MERIT40 Mutation screening [30]
GWAS [22]
N. I.
rs8170 [22]
BRCC45 Not done -
BRCC36 Not done -
a Homozygous mutations in this gene have been demonstrate to result in
RIDDLE syndrome [12].
GWAS, genome wide association study; N. I., not identified.
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software for potential splicing effects http://www.fruitfly.
org/seq_tools/splice.html.
Results
The mutation analysis of RNF8 revealed two exonic, two
intronic and three 5’UTR variants. Only one of these
variants was novel (not reported the NCBI SNP data-
base, http://www.ncbi.nlm.nih.gov/SNP/). Both of the
observed exonic variants of RNF8 were synonymous. In
the UBC13 gene, one unreported and one known intro-
nic variant were observed, whereas no sequence altera-
tions were observed in MMS2. All observed alterations
in RNF8 and UBC13 were assessed for possible effects
on consensus splice sites, but none of them had a pre-
dicted effect on splicing. In order to evaluate possible
pathogenicity of the observed changes, their frequencies
were compared between cases and healthy control indi-
viduals. None of the found sequence changes, however,
appeared to associate with breast cancer susceptibility
(Table 3).
Discussion
RNF8, UBC13 and MMS2 have important roles in the
maintenance of genomic integrity and cell-cycle check-
point control [9-11,19]. Based on their involvement in
DDR and importance in BRCA1-mediated DNA damage
recognition it was considered possible that mutations in
these genes might contribute to hereditary predisposi-
tion to breast cancer.
In the current study, the whole coding region of the
RNF8, UBC13 and MMS2 genes was systematically
screened for mutations in 123 breast cancer families. No
deleterious sequence alterations were observed in any of
the genes. Previous studies have suggested that the
RNF8 gene could be novel tumor suppressor [17], but it
seems that germline mutations predisposing to breast
cancer in this gene do not exist or, at least, are very
r a r e .I ti so fi n t e r e s tt h a ta n o t h e rE 3l i g a s e ,R N F 1 6 8 ,
which acts together with UBC13 to amplify the RNF8-
dependent histone ubiquitylation has been shown to be
defected in RIDDLE syndrome, which is an immunode-
ficiency and radiosensitivity disorder. However, it is still
unclear whether RIDDLE syndrome is associated with
genome instability or increased tumor incidence [12].
Conclusion
The present data suggest that mutations predisposing to
breast cancer are either very rare or absent in the cod-
ing region of the RNF8, UBC13 and MMS2 genes,
which could possibly point to the essentiality of their
protein products in the DNA damage response and
other functions maintaining genomic integrity. Although
a small study like this cannot exclude the possibility of
some other rare mutations in RNF8, UBC13 and MMS2
might predispose to breast cancer, based on our findings
they unlikely make any sizeable contribution to cancer
predisposition. To our knowledge, this is the first study
reporting the mutation screening of the RNF8, UBC13
and MMS2 genes in familial breast cancer cases.
Table 2 Primers used for the screening of RNF8, UBC13 and MMS2
Gene Exon Forward primer (5’-3’) Reverse primer (5’-3’) PCR fragment size (bp)
RNF8 1 GCGAGGAGACCTCTCGAATC TCCTCTCTGCCATTCATTCA 498
2 TGCTGCTGGTTGATGAGAT AAATAAAAGTCATTAGGCTTCTG 250
3a AAGAAGACGAAAATCATGAAGC TAATTCATCCAAACTGAATTTCC 294
3b CCTTGTCTTTCCCCAAAGAAT TTACTTGGCTCAAGGGCAGT 242
3c AGTGGCCAGTACACCCTCTG TTCACATTCATAACGGCTTCA 240
3d GGTGACCATGTCCAGGATTC AAGACCACTCTTGCCCTTCC 260
4 CAGGAGATTTTCCACCTGCT GGTCATGTGATGCCTGTTTG 271
5 CAGGCATGTTTGTGGCTAAA CCTAGCAACCCTTGCACTGT 242
6 CCTGTCCCATTTTGCATTTT AAGGGGTGAGCAACTGTTC 197
7 GCCCTTAAGATGGGATTGTTG TCCCTTTACTCCTCCCCATT 483
8 AGGGAAATACAGGCTCCTCA CAAGTGACTGAGGGCTTCCT 220
UBC13 1 GACTTCCACTCGTGCGTGA TCCTCAGCACCCGACTTC 264
2 TTGGGAGATTGGAGCTGTTC TGGAATGCTTAAGAGAAAAAGGA 430
3 GTCTGTGGGAGGGAAGTGAA CCCATAGCAAGCCATTTTGT 385
4 ATCTTTCAGCCCTGATCCAA GAGGGGCCACTGCTTTTA 448
MMS2 1 CCCGGCCCTCATGAACTT GGTCCCAGGCTACGCTCT 411
2 AGGGGATTTGGTCTTTTTGG CACGTGGGAAGCATCAATAA 421
3 GCACTTAGACATTAATATTTTAGGTA TTTTGGCTTAACAAAGGTCCTC 331
4 TGCTTAACAAATTGGTGCCATA GCTGCATTTTTCCTCCTGTT 408
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